Trials / Terminated
TerminatedNCT03927573
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- AvenCell Europe GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to respond to standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GEM3PSCA | Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles |
Timeline
- Start date
- 2019-04-15
- Primary completion
- 2023-06-28
- Completion
- 2023-06-28
- First posted
- 2019-04-25
- Last updated
- 2023-07-10
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03927573. Inclusion in this directory is not an endorsement.